PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-30.95%
Both yoy net incomes decline, with RVPH at -5.73%. Martin Whitman would view it as a broader sector or cyclical slump hitting profits.
-12.50%
Negative yoy D&A while RVPH is 0.00%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
No Data
No Data available this quarter, please select a different quarter.
-0.29%
Both cut yoy SBC, with RVPH at -2.73%. Martin Whitman would view it as an industry shift to reduce stock-based pay or a sign of reduced expansions.
710.07%
Well above RVPH's 81.57% if positive yoy. Michael Burry would see a risk of bigger working capital demands vs. competitor, harming free cash flow.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
478.18%
A yoy AP increase while RVPH is negative at -154.89%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
8.45%
Lower 'other working capital' growth vs. RVPH's 104.15%. David Dodd would see fewer unexpected short-term demands on cash.
-100.00%
Negative yoy while RVPH is 56.10%. Joel Greenblatt would see a near-term net income or CFO stability advantage unless competitor invests or writes down more aggressively.
-8.11%
Negative yoy CFO while RVPH is 27.71%. Joel Greenblatt would see a disadvantage in operational cash generation vs. competitor.
100.00%
CapEx growth of 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz would see a mild cost burden that must yield returns in future revenue or margins.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
100.00%
We expand invests by 100.00% while RVPH is zero at 0.00%. Bruce Berkowitz sees a moderate outflow that must be justified by returns vs. competitor’s stable approach.
-50.00%
Both yoy lines negative, with RVPH at -137.50%. Martin Whitman suspects an environment prompting net new borrowings or weaker paydowns across the niche.
-32.24%
Negative yoy issuance while RVPH is 0.00%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
No Data
No Data available this quarter, please select a different quarter.